Comparison of high dose therapy of rhEPO, given two or three times a week in premature infants.
We investigated the question whether there is a difference in the response to high dose human recombinant erythropoietin (rhEPO) given twice or three times weekly in premature infants. 48 premature infants were randomly assigned to receive 300 U/kg rhEPO three times a week or 450 U/kg two times a week for at least 4 weeks and up to 6 weeks. Concomitant oral iron supplementation was compulsory, median daily dosage reached 6.6 mg/kg, doses exceeding 8 mg/kg/d were not tolerated. Our data showed no differences in the two groups in regard to hematocrit (HCT), reticulocytes and ferritin levels. A marked increase in reticulocyte counts could be observed in both groups. Serum ferritin decreased as expected. Premature infants starting with a baseline HCT lower than 32% showed a steady increase in HCT without any initial decline. No adverse effects could be observed in either group. Since there is no difference in the response to high dose rhEPO given two or three times weekly, we therefore conclude that the twice weekly regimen is compatible with outpatient treatment.
Bock
W
W
Children's Hospital, Kinderklinik Glanzing, Vienna, Austria.
Gröhs
B
B
Minihold
B
B
Schemper
M
M
Lischka
A
A
D000740:Anemia / Q000097:blood / Q000517:prevention & control*; D001803:Blood Transfusion; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000517:prevention & control*; D007501:Iron / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron